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Central venous catheters (CVC) are integral tools used in blood stem cell transplant with 
registered nurses responsible for maintenance and catheter care.  However, CVC practice 
guidelines in the literature are inconsistent or absent.  Gaps in the evidence generated 
several research questions regarding potential variability in CVC practice across Canada 
and the impact that variability may have on healthcare spending and patient outcomes.  A 
survey revealed differences in CVC practice across Canada that coincide with discrepant 
and/or absent guidelines.  Current cost-analyses within the blood stem cell transplant 
population were also absent in the literature.  The cost of a single CRBSI was estimated 
using a case controlled comparison of records.  The study quantified how costs can be 
contained through prevention efforts, and identified the importance of nursing research 
targeting infection control.  One prevention area was tested in terms of infection 
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outcomes with tunneled catheters used by blood stem cell transplant recipients.  The 
descriptive study compared three different nursing strategies for CVC exit site care in 
terms of CRBSI and cost.  Results indicated each strategy poses similar CRBSI risks with 
significant differences in expense.  Maximum value was attributed to transparent 
dressings followed by removing the dressing and lastly using a gauze dressing. The no 
dressing strategy was a more cost-effective alternative when a transparent dressing 
cannot be tolerated.  Further analysis of the data generated in this project is ongoing with 
the intent to delineate other areas of nursing influence on CRBSI and identify further 
potential areas for cost containment.  
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Chapter One:  Introduction 
 Mature cells in the human body stem or originate from a parent cell.  The first cell 
in a lineage of cell chains that differentiate until maturity is often defined as a stem cell.  
There are many types of stem cells throughout the body that are the focus of transplant 
research.  Hematopoietic or CD34 stem cells are sourced in the bone marrow and 
responsible for the production of several cell chains that eventually develop into the 
blood supply (Tomblyn et al., 2009).  Certain hematological disorders interfere with 
normal blood and marrow functioning which may require a blood stem cell transplant.  
The basics of blood stem cell transplant are to eliminate abnormal cells and introduce a 
new source for healthy blood production.  The source of stem cells used for transplant has 
given rise to different terms and medical acronyms.  Transplanted stem cells may be 
given within a volume of bone marrow, otherwise known as a bone marrow transplant 
(BMT).  Hematopoietic progenitor cell transplant (HPCT) uses isolated stem cells that 
are filtered from the bloodstream of the donor through a process known as apheresis.  A 
cord transplant uses stem cells collected from a donated umbilical cord.  BMT, HPCT, 
and cord transplant are all subcategories of the broader blood stem cell transplant (SCT) 
population.   
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 Scientific progress, albeit beneficial, has increased hospital patient acuity outside 
of Intensive Care Units.  Registered nursing care with acute populations often requires 
advanced competency training.  Blood stem cell transplant nurses possess specialty 
knowledge for delivering treatments such as chemotherapy, blood products, and 
biologicals etc.  These nurses must also develop skillful assessment abilities for 
monitoring critically ill patients, managing symptoms, and alleviating side effects of 
treatment.  Complications faced by blood stem cell transplant recipients include weight 
loss, nausea, and graft versus host disease; however, infection predominates, occurring in 
over 60% of patients (Weissinger et al., 2011).  Infection during acute transplant and 
beyond increases reliance on registered nursing care as several behaviors, actions, 
interventions, and facilitation of the multidisciplinary team are needed to address 
occurrence.   
 Central venous catheters (CVC) are an integral part of blood stem cell transplant 
nursing and a potential source of infection.  Removing the dressing from the healed exit 
site of a tunneled CVC is a recent trend in the industry.  In clinical practice, this author 
has observed the implementation of policy changes such as dressing removal with little 
explanation or provision of supporting evidence. Westbrook, Duffield, Li, and Creswick 
et al. (2011) point out that registered nurses work in such a high paced environment that 
they only spend around 37% of their time with patients.  Majid et al. (2011) report that 
registered nurses in Singapore claim they are unable to keep up to date with current 
evidence due to heavy workloads.  Findings suggest staff nurses entrust nurse leaders to 
expedite the dissemination of evidence that is incorporated at the bedside.  Questionable 
policy changes may foster slow change or even initial non-adherence as was observed in 
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personal practice.   Whether the dressing on a healed tunneled CVC exit site should be 
removed or maintained depends on the standpoint of the consulting panel.  (Gillies, 
O’Rordan, Sheriff, & Rickard, 2011; Infusion Nurses Society, 2011; O’Grady et al., 
2011; Olsin et al., 2004; Scales, 2010b; Seiler & Pember, 2012; Toshiyuki et al. 2012).  
Gaps in the evidence coupled with recent changes mandating dressing removal at the 
authors clinical practice site generated the research questions for this project.   
 Canada does not have universal practice standards for CVC nursing care.  
Initially, it was unclear if removing the dressing from a healed tunneled CVC exit site 
was becoming a baseline nationwide care strategy.  Boersma and Schouten (2010) 
reported that care differences occur in elements of CVC care when there are unclear 
positions on the best course of action.  It was hypothesized that CVC practice in blood 
stem cell transplant also differs across Canada which may result in excess healthcare 
spending and different outcomes.  Subsequently, a descriptive survey of Canadian 
practice was planned and conducted in the summer of 2013 (Appendix A) following 
university institutional review board (IRB) approval (Appendix B).  This initial survey, 
reported in Chapter Two, notes similar findings to Boersma and Schouten (2010) 
revealing differences in CVC practice across the nation that coincide with discrepant 
and/or absent CVC guidelines.  Results of the study are currently in press according to 
the author guidelines in Appendix C, and publisher permission to include the manuscript 
in this portfolio was granted (Appendix D). 
 Following the initial survey study, it was unclear if CVC care differences pose the 
same risks for negative outcomes.  Device-associated complications such as catheter-
related bloodstream infection (CRBSI) are costly and avoidable.  The literature did not 
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contain Canadian estimates of CRBSI costs beyond one study that only considered fees 
for extended length of hospital stay (Raschka, Dempster, & Bryce 2013).  The unique 
needs of the blood stem cell transplant population and use of one specific type of CVC 
among 90% of centers surveyed in the first study directed research attention to the need 
to determine the cost of a single CRBSI alongside a planned study comparing negative 
outcomes among CVC dressing strategies.  Understanding costs associated with the 
different dressing strategies was an integral first step to determining if one particular 
strategy was more effective in terms of preventing infection and the cost effectiveness 
associated with the various dressing strategies.  University IRB and ethics board approval 
from the practice site (Appendix B) were secured for implementing a two-pronged study 
to examine costs associated with CRBSI and to determine the incidence of CRBSI among 
patients whose CVC sites were maintained using one of three dressing strategies. 
 The cost of a single CRBSI was estimated using a case controlled comparison of 
records and is reported in Chapter Three.  Study results quantified CRBSI in Canadian 
dollars, thus informing how costs can be contained through prevention efforts and 
identifying the importance of nursing research targeting infection control.  Concomitant 
examination of CRBSI with different exit site dressings was compared as planned.  
Asepsis theory guided variable selection (Duval, 2010).  Tenets of the theory portray co-
existence versus pathological relationships between hosts and micro-organisms that can 
be influenced by clinical actions.  The descriptive study compared three different nursing 
strategies for CVC exit site care (transparent dressing, no dressing, or gauze dressing) in 
terms of CRBSI and fees for supplies.  Results from this study are reported in Chapter 
Four.   
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 Findings from this emerging program of research have the potential to influence 
blood stem cell transplant nursing practice in Canada and across the globe.  These studies 
provide empirical data to help clinicians make informed and evidence-based practice 
decisions that may lead to improved patient outcomes and responsible fiscal practices.    
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Chapter Two:  Central Line Practice in Canadian Blood and Marrow Transplant 
Abstract and manuscript prepared for the Canadian Oncology Nursing Journal (in 
Press) 
Abstract 
 
More than 800 blood cell and bone marrow transplants are performed annually 
in Canada to treat fatal cancers and rare blood disorders. Central vascular 
access is fundamental in blood and marrow transplant nursing to facilitate 
chemotherapy and blood product infusions. A tunneled Central Venous 
Catheter (CVC) is the vascular access device-of-choice in the cell and 
marrow transplant population. Several practice guidelines direct nursing 
policy and procedure for CVC management and care. CVC insertion and 
removal guide- lines are increasingly relevant given the widening scope of 
advanced practice nursing. Unresolved issues are noted among the most 
heavily cited CVC practice recommendations accessible via the Centers for 
Disease Control and Prevention (CDC). A descriptive survey based on the 
CDC guidelines was conducted to identify potential variability in CVC 
strategies in Canadian blood and marrow transplant nursing. Survey results 
indicate nationwide differences in catheter site selection, educational 
strategies, dressing strategies, delegation of dressing changes, and volumes 
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of flushing and locking solutions used to manage catheter patency. 
Variability in practice coincides with gaps in the evidence identified in 
practice recommendations. Future studies comparing specific care approaches 
to device-associated complications are needed to resolve issues and strengthen 
practice guidelines. 
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Chapter Two:  Central Line Practice in Canadian Blood and Marrow Transplant 
 Blood cell and/or bone marrow transplant is conducted for certain life-
threatening diseases and blood cancers. Transplant involves obliterating the 
bone marrow followed by repopulation with donated cells. Tomblyn et al. 
(2009) explain that disease is both targeted and eradicated by proxy through 
destroying the system of origin. The curative aim of treatment is for 
transplanted donor cells to manufacture a new disease-free blood supply within 
the recipient. Procedurally, blood and bone marrow transplant is provided 
through intravenous infusions of chemotherapy, supportive medications, fluids, 
and transfusions of blood products including donor cells. A central venous 
catheter (CVC) is one type of vascular access device that was specially 
developed for complex medical care by enabling long term use, exchange of 
large fluid volumes, and delivery of medications caustic to peripheral veins 
(Scales, 2010). Patients describe a CVC as instrumental towards cure because it 
is the portal for delivering treatment (Møller & Adamsen, 2010). 
 CVC care and management, as well as patient education, are 
primarily the responsibility of registered nurses in Canada. Given that risks 
are associated with using medical devices patient safety is a central concern. 
Pneumothorax, infection, and thrombosis are examples of complications 
associated with CVC use (Kim et al., 2010; O’Grady et al., 2011). Infection
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is of particular concern with the cell transplant population given their 
weakened immunity from disease and treatment (Tomblyn et al., 2009). 
Nursing policy and procedures routinely incorporate study findings that 
correlate CVC care strategies with minimized risks. However, at present, 
there remain gaps in the evidence to support nursing practice in this area. 
Boersma and Schouten (2010) found that actual CVC practices vary across 
Europe as a manifestation of discrepant and/or absent practice guidelines. It 
is not known what the adherence to guidelines regarding CVC care is across 
Canada. 
 Several jurisdictions provide clinical practice guidelines for CVC 
competency including insertion, routine care, maintenance, and removal 
(Appendix A). The recommendations by O’Grady et al. (2011) are the most 
frequently cited in North America given open access via the American Centers 
for Disease Control and Prevention (CDC) and collaboration with several 
expert panels. Unresolved issues noted by O’Grady et al. (2011) point out gaps 
in the evidence concerning CVC care and management worth future research 
attention. Specific issues in blood and marrow transplant nursing described in 
the report are that no evidence-based recommendations can be made for optimal 
site selection for the catheter, optimal dressing type, removing the dressing 
from a healed tunneled CVC site, or managing catheter patency. Periodic 
competency training is also encouraged with no clear stance on frequency. 
Policy makers and Registered Nurses are faced with distinguishing between 
conflicting recommendations and using practice-based approaches when 
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evidence is lacking. The purpose of this descriptive study was to examine 
adherence to recommended CVC guidelines within the Canadian blood and 
marrow transplant population and identify potential nationwide variability in 
care strategies to be tested in future research. 
Method 
 The study was approved by the institutional review board at the 
University of Texas at Tyler. As no other instrument existed, a descriptive 
survey was created for the purposes of this study, based on infection prevention 
guidelines for intravascular catheters by O’Grady et al. (2011). The survey 
included 33 questions of inquiry in four areas related to the tunneled CVC 
commonly used in blood and marrow transplant: insertion, routine care, 
maintenance, and removal. Survey questions contained various response 
options: yes or no choices, multiple choice, and open-ended formats.  The survey 
was electronically distributed to 25 centres within the 14 blood cell and bone 
marrow transplant programs across Canada. A purposive sample of advanced 
practice nurses, nurse educators, managers, and program coordinators in blood 
and marrow transplant was invited to voluntarily answer questions regarding the 
CVC policy at their centre. One response per centre was accepted. A draw for a 
$50 gift card was used as an incentive for participation. 
Results and Interpretation 
 
 Thirteen  respondents  returned  surveys  and  indicated  provision of blood 
cell and/or  bone  marrow  transplant  at  their  centre (Appendix B).  Three 
surveys were omitted from the analysis, as only the first two demographic 
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questions were answered, for a total response rate of 40% (n=10). Responses 
included in the analysis represent both inpatient and outpatient settings treating 
adult (70%) and pediatric (40%) patients, seven of eight provinces offering 
blood and marrow transplant, and approximately 67% of the Canadian blood and 
marrow transplant population (Canadian Blood and Marrow Transplant Group, 
2013).  
 The survey results reveal that variations in CVC practice coincide with 
discrepant and/or absent guidelines in the areas of competency training, 
insertion, routine care, maintenance, and removal. CVC practice is reported as 
the duty of physicians and nurses with overlapping responsibility for insertion, 
dressing changes, and removal. Forty per cent of centres indicated that CVC 
care is also delegated to patients, family members, and lay caregivers. 
Competency in CVC care requires learning skills, the rationale for device use, 
and how to avoid complications. Studies recommend targeted education to 
maintain vigilance with care and avoid human error (Faruqi et al., 2012; 
Rosenthal, 2009). All survey respondents reported that their centre has a policy 
in place to educate staff on insertion, routine care, and maintenance of a CVC. 
All centres that delegate routine care reported having a policy in place for 
educating patients, families, and lay caregivers. Sixty per cent of centres repeat 
CVC education annually while the remaining centres only rein- force policy 
changes. Different educational strategies coincide with the subjective 
recommendation by O’Grady et al. (2011) to periodically evaluate knowledge and 
concordance with recommended guidelines. 
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Insertion 
 Survey responses indicate CVC insertion is a physician responsibility in 
the majority of cases and adherence is fully observed in avoiding prophylactic 
antibiotics, avoiding femoral veins, and using tunneled or implanted catheters. 
Only one centre (10%) reported the use of antimicrobial impregnated cuffs 
which O’Grady et al. (2011) claim is only necessary with persistent infection 
in spite of prevention efforts. Instead, it is advised to employ multiple infection 
prevention strategies, known as bundling. CVC insertion bundling consists of: 
proper hand hygiene, using maximum barrier precautions (sterile gown, drape, 
gloves, equipment, and wearing a mask), using a >.5% chlorhexidine skin prep 
solution, choosing the appropriate site if known, and daily review of the 
necessity of the catheter with prompt removal when no longer essential (Faruqi 
et al., 2012; Moreau, 2009). Supervision for inexperienced practitioners and use 
of ultrasound guidance is also recommended to reduce the risk of insertion-
related complications (Shekelle et al., 2013). In the survey results, adherence to 
bundling insertion strategies and use of ultrasound guidance was unknown by 
the responding nurses. Of note, the procedure is out of nursing practice scope in 
the majority of settings. The reported variation regarding insertion site selection 
coincides with the lack of evidence supporting subclavian over intra jugular 
sites, or one side of the body over the other (Ge et al., 2012). Awareness of 
insertion guidelines is increasingly important given advanced practice nurses 
are beginning to engage in line placement (10%).  
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Routine Care and Maintenance 
 There is general consensus in the literature that a newly inserted CVC 
is covered with a dressing, not submerged in water, and has an extra covering 
for showering. However, the optimal dressing material to use remains unclear 
(Gillies, O’Riordan, Sheriff, & Rickard, 2011). There is also consensus in the 
literature on the type of skin antiseptic to be used (>0.5% chlorhexidine or 70% 
alcohol, tincture of iodine, or iodophor for infants or allergies) and frequency 
of gauze or transparent dressing changes at 48 hours or after seven days 
respectively (Infusion Nurses Society, 2011; O’Grady et al., 2011; Scales, 
2011). All centres surveyed reported full adherence to recommendations 
specific to gauze or transparent materials and use of barriers and aseptic 
techniques for line care. However, 20% reported no additional protection is 
used for showering. Non-adherence to the recommendation may be due to the 
waterproof capability of a transparent dressing, which is the most commonly 
used material (90%) to cover a CVC exit site. Case studies report the 
elimination of water-borne bloodstream infection when using a waterproof 
covering for hygiene, even when a dressing is used on a CVC exit site, as the 
strategy provides added protection against colonization of caps and 
connections from tap water (Baird et al., 2011; Toscano et al., 2009).  
 Another variation in practice across Canada coincides with the discrepancy 
in views about maintaining or removing the dressing from a healed tunneled exit 
site. The most recent Cochrane meta-analysis comparing dressing materials 
reported no study designed to draw comparisons with a “no dressing” group 
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(Gillies et al., 2011). Forty per cent of the centres surveyed in this study reported 
that healed tunnel sites are left open to air. The 2011 guidelines from the 
Infusion Nurses Society (INS) cite only one study supporting the no-dressing 
recommendation while the CDC remains irresolute on the issue.   
 Links between the inflammatory and coagulation response in the 
bloodstream interrelate infection and thrombosis (Levi, van der Poll, & Schultz, 
2012). The correlation of cumulative infection and thrombotic risks in cancer 
patients with a CVC highlights the importance of prevention strategies (Hitz et 
al., 2012; Rowan et al., 2013). All centres reported CVC patency is maintained 
with normal saline flushing and heparin locking, though no centre used the 
same combinations or volumes. The INS (2011) defers maintenance decisions to 
instructions by product suppliers. Camp-Sorrell (2010) notes manufacturer 
recommendations continue to dictate care without providing current supportive 
evidence of product effectiveness versus complications. Varying volume and 
concentration types of locking solutions across Canada speak to the lack of 
guidance for preventing catheter occlusion which may, in turn, influence 
infection rates. Dibb et al. (2012) agree that maintaining the integrity of a CVC 
through the use of anti-coagulants and antimicrobial locking solutions may be a 
feasible approach to preserving central access while admitting more evidence is 
needed. All respondents in this study reported that attempts are made to 
salvage sluggish and/or occluded lines with  anti-coagulants, and 60% indicated 
the  use of anti-infective locking solutions are options for managing known 
infections. Practice guidelines for preventing infection do not speak to 
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thrombotic correlations, do not advise anticoagulant use for the purpose of 
preventing catheter-related bloodstream infection, and caution against use of 
anti-infective locking solutions unless repeat infections are problematic 
(O’Grady et al., 2011). Sodium citrate is one suggested multipurpose locking 
solution approved for use in Canada, though no centre in this survey reported 
use of the product (O’Grady et al., 2011). 
Removal 
 Catheter-related infection, malfunction, or total occlusion may necessitate 
early line removal or replacement. Similar to insertion, CVC removal was 
reported in this study as primarily a physician responsibility with delegation to 
nurses in 20% of situations. Line removal is not recommended based on fever 
alone but is consistently advised for unnecessary catheters (INS, 2011; O’Grady 
et al., 2011; Tomblyn et al., 2009). Twenty per cent of the centres do not adhere 
to prompt removal however results may be limited to the subjective interpretation 
of necessity by the nurses surveyed. 
Discussion 
 The results of a descriptive survey of Canadian CVC practice support 
similar findings in Denmark and the Netherlands by Boersma and Schouten 
(2010). When issues concerning CVC care remain unresolved in the literature, 
it poses clinical dilemmas for clinicians. Practice-based decisions often guide 
CVC care approaches when evidence is lacking or discrepant. Practice 
guidelines are not provided with the intent to replace clinical judgment rather 
they serve to narrow variability when there is convincing evidence supporting 
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certain care strategies over alternatives. Adherence to resolute guidelines 
depends on awareness of disseminated findings and time needed to incorporate 
findings into practice. Program accreditation is one option for ensuring 
minimum care standards within certain treatment areas. Regimented 
competency training may also ensure that diligence is maintained in practice. 
Care standards can only assist in mitigating risks when sufficient data are 
available. Gaps in the evidence may lead to different care approaches being 
adopted that may result in differences in clinical effectiveness. Strengthening 
evidence through research is still needed in several aspects of CVC practice. 
 The plethora of available central venous access devices and variation in 
patient requirements for care points to the need for population-centred 
inquiries. Camp-Sorell (2010) notes that best practice is often identified 
through measuring systematic practices against outcomes. Studies comparing 
different CVC care approaches to infection and thrombosis rates may 
provide pragmatic resolutions to existing practice discrepancies. Measuring 
overlapping constructs contributes to a bank of insufficient findings that are 
often excluded from meta-analysis (Ge et al., 2012). Examining specific 
vascular access devices within specific clinical populations should be 
considered for controlling construct validity. Variable practice and 
unresolved issues for recommendations point to the need for future dressing 
studies with tunneled CVCs, including comparisons to a “no-dressing” 
group. Mathers (2011) notes the absence of standard flushing protocols for 
central access across America, which coincides with these survey results of 
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Canadian practice. Empirical studies testing the effectiveness of particular 
flushing and locking solutions with specific devices in specific populations 
are needed for the development of practice guidelines. 
Conclusion 
 Medical advances have allowed complex treatment for uncommon 
diseases. Central vascular access devices are commonplace in specialty areas 
treating acutely ill patients. Registered and Advanced Practice Nurses are in a 
position of positively influencing the incidence of complications with medical 
devices. Incongruent practice advice and gaps in evidence manifest in different 
care approaches worth research attention as variable practice may inadvertently 
propel disparate care. Results from the descriptive study of CVC practice 
across Canada indicate some centres do not fully adhere to all recommendations 
and that variable care approaches coincide with discrepant advice and gaps in 
evidence. Studies focusing on preventing catheter-related occlusions and 
infections have the potential to increase care quality. Incorporating the study of 
the cancer system capacity when investigating practice comparisons may, 
provide additional validation of nursing influence. 
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Appendix A 
Table1 
 Recommendations for CVC Practice 
Location Advisory Access 
Australia Australian Society for 
Parenteral and Enteral 
Nutrition (AuSPEN) 
www.healthinfonet.ecu.edu.au 
 Center for Health Care 
Related Infection 
Surveillance and Prevention 
(CHRISP) 
www.health.qld.gov.au/chrisp 
 Australian Commission on 
Safety and 
Quality in Health Care, 
National Safety 
and Quality Health Service 
Standard 
www.health.qld.gov.au 
Canada BC Cancer Agency www.bccancer.bc.ca 
 Canadian Patient Safety 
Institute (CPSI) 
www.saferhealthcarenow.ca 
 Public Health Agency of 
Canada:  Canadian 
Nosocomial Infection 
Surveillance Program 
(CNISP) 
www.phac-aspc.gc.ca 
 
 Registered Nursing 
Association of Ontario 
(RNAO) 
rnao.ca 
Europe European Center for 
Disease Prevention (ECDC) 
ecdc.europa.eu 
 European Society for 
Clinical Nutrition and 
Metabolism (ESPEN) 
www.espen.org 
 
Global International Federation of 
Infection Control (IFIC) 
www.theific.org 
 
 World Health Organization www.who.int/csr/resources/publications/dru
gresist/en/whocdscsreph200212.pdf 
Japan Ministry of Health, Labour, 
and Welfare 
www.mhlw.go.jp/english/index.html 
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Appendix A (Continued) 
New 
Zealand 
Intravenous Nursing New 
Zealand (IVNNZ) 
www.ivnnz.co.nz 
United 
Kingdom 
British Committee for 
Standards in Hematology 
(BCSH) 
www.bcshguidelines.com 
 National Institute for 
Clinical Excellence (NICE) 
www.nice.org.uk 
 Royal College of Nursing www.rcn.org.uk 
United 
States 
American Society of 
Critical Care 
Anesthesiologists (SOCCA) 
www.socca.org 
 
 Center for Disease Control 
and Prevention (CDC) 
www.cdc.gov 
 Infectious Disease Society 
of America (IDSA) 
www.idsociety.org/Index.aspx 
 Infusion Nurses Society www.ins1.org 
 Society for Healthcare 
Epidemiology of America 
(SHEA) 
www.shea-online.org 
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Appendix B 
Table 2 
Survey Responses 
 
Adult inpatient 7 
(70%) 
Adult outpatient 3 
(30%) 
Pediatric inpatient 3 
(30%) 
Pediatric outpatient 1 
(10%) 
Transplant 
     Blood Cell 
     Bone Marrow 
     Cord 
     Progenitor Stem Cell 
 
62% 
85% 
54% 
85% 
Transplants per Year 
     <50 
     51-100 
     >100 
 
30% 
30% 
40% 
Staff Education 100% Patient Education 80% 
Insertion 
Use of Prophylactic Antibiotics 0% Use of Tunneled Line 80% 
Insertion Bundle 
     Yes 
     Unknown 
 
60% 
40%  
Use of Antimicrobial Devices  
     Yes 
     Unknown 
 
10% 
50%  
Under Ultrasound Guidance  
     Always 
     Unknown 
 
30% 
70% 
Placement 
By a Physician 
By a Specialty Nurse 
 
90% 
10% 
Preferred Site 
     Physician Choice 
     No Preference 
     Right Subclavian 
     Left Subclavian 
     Right Intra jugular 
 
30% 
30% 
20% 
10% 
10% 
Preferred Number of Lumens 
     Two 
     Three 
 
40%  
60%  
Routine Care and Maintenance 
Use Dressings 
     Gauze (changed every 2 days   
     when used) 
     Transparent (changed 
weekly 
     when used) 
     None (after tunnel healing) 
100% 
100% 
 
90% 
40% 
Managing Patency 
     Flushing with Normal Saline 
     Heparin Locking 
     Locking with Normal Saline 
     Alteplase 
     (Suspect/Known Occlusion) 
 
100% 
90% 
10% 
100 
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Appendix B (Continued) 
Dressings Changes 
Performed By 
     Registered Nurse 
     Licensed Practical Nurse 
     Patient 
     Family/Lay Caregiver 
     Specialty Nurse 
     Physician 
 
100% 
10% 
30% 
50% 
20% 
10% 
Preventing Infection 
     Covering in Shower 
     2% Chlorhexidine Skin Prep 
     70% Alcohol Skin Prep    
     >.5% Chlorhexidine Skin Prep   
     Antimicrobial Locking     
     (known infection) 
 
 
80% 
60% 
30% 
10% 
60% 
Nursing Time for Dressing 
Change 
     15 minutes or less 
     15-30 minutes 
 
60% 
40% 
Removal 
Removal By 
     Physician 
     Specialty Nurse 
     Registered Nurse 
 
90% 
10% 
10% 
Replacement Indicated 
     Known Infection 
     Known Occlusion 
     Malfunction 
     Unresolved Complication 
 
100% 
90% 
80% 
20% Prompt Removal When no 
Longer Necessary 
80% 
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Chapter Three:  The Economic Burden of Catheter-Related Bloodstream Infection 
in Canadian Blood Stem Cell Transplant 
Abstract 
Catheter-related bloodstream infection (CRBSI) is associated with increased healthcare 
spending and patient morbidity.  The purpose of this study was to estimate the direct 
inpatient charges for CRBSI in Canadian blood stem cell transplant recipients with a 
tunneled Central Venous Catheter (CVC).  A case-controlled comparison of records 
indicating CRBSI and records not indicating CRBSI was used to quantify charges across 
the following domains:  length of stay, laboratory tests, diagnostic tests, medications 
used, consults to a specialty physician, catheter replacement costs, and length of stay in 
the Intensive Care Unit.  Infections reduced the length of catheter use time by an average 
of 13.51 days.  Patients with CRBSI stayed on average an extra 19.81 days in the 
hospital, resulting in extra charges of $40,986 for base 24-hour stay.  Extra fees for 
directly diagnosing and treating CRBSI averaged $4,683.90.  Thus, the total estimated 
burden of CRBSI in Canadian blood stem cell transplant for the 2013 fiscal year was 
$45,670.79 per incident.   
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Chapter Three:  The Economic Burden of Catheter-Related Bloodstream Infection 
in Canadian Blood Stem Cell Transplant 
Microbial resistance confronts efforts to control infection in healthcare.  Coupled 
with patient acuity, infection further strains organizational budgets.  Cancer patients 
possess intrinsic risks for infection with compromised immune function being the most 
serious (Bereket et al., 2012).  A central venous catheter (CVC) is commonly used in 
cancer care for delivering therapeutics and blood sampling (Scales, 2011).  The devices 
provide a direct portal to the bloodstream and because of this there is a potential for 
contamination.  Boersma and Schouten (2010) caution against acquiescence of infection 
with healthcare technology.  Infection control measures can be effective for ensuring 
safety with the use of medical devices including a CVC.       
Patrick et al. (2013) found central line infection is grossly under-reported 
compared to the findings from the audits of medical records.  This finding undermines 
ethical accountability in healthcare provision.  Scrutiny of hospital infection rates 
challenges administrators to ensure control measures are positively influencing outcomes.  
Certain hospital-acquired infections are avoidable with evidence-based prevention 
strategies that target extrinsic risk factors (Bereket et al., 2012).  Hand washing for 
example, reduces transfer of microbes from one surface to another.  Due diligence in 
preventing infection alleviates morbidity and mortality risks that are especially 
threatening to cancer patients.  Currently, the costs of catheter-related bloodstream 
infection (CRBSI) in blood stem cell transplant are unknown.  The purpose of the study 
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was to estimate inpatient direct medical care charges for CRBSI in Canadian 
blood stem cell transplant recipients with a tunneled triple lumen subclavian CVC. 
Review of the Literature 
CRBSI 
 Catheter insertion, handling connections, or (rarely) infusions are all gateways for 
transmission of pathogens (O’Grady et al., 2011).  Bacterial affinity for surfaces in the 
form of biofilm may also colonize onto catheter surfaces causing infections that are 
problematic to eradicate (Yasuhiko et al., 2012).  Determining that an infection is related 
to a catheter involves assessment and ruling out all other potential sources.  The 
Infectious Diseases Society of America (IDSA) cites criteria for diagnosing CRBSI, 
which practice consultants distinguish as different than a central-line associated 
bloodstream infection (CLABSI) (O’Grady et al., 2011; Mermel et al., 2009).  Lab 
confirmation using comparative blood cultures with differences in growth time and 
overall quantity of organisms more accurately reflect if organisms are sourced in (and 
likely introduced from) a catheter (CRBSI) versus surface seeding or introduction from 
other portals (CLABSI).   
Cost 
The majority of cost analyses report findings from intensive care settings.  The 
Centers for Disease Control and Prevention (CDC) reported in 2005 that the cost of a 
single CLABSI exceeds $25,000 United States Dollars.  Hsu et al. (2013) note cost 
differences vary widely, depending on hospital reimbursement rates in multi-payer 
healthcare models.  In addition to the payment model Table 3 summarizes costs reports of 
a single incident with varying estimates due to currency values, clinical population, and 
timing of the research.   
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Table 3 
Case Control Cost Analyses of a Single Central Line Infection 
Authors/  
Year 
Country Cost Population Measures 
Orsi, et al. 
(2002) 
Italy €16,356 ICU 
(surgical) 
Extra charges for extended 
length of stay and infection 
treatment
 
Liu et al. 
(2002) 
Taiwan $NT66, 302 Renal Dialysis Extra charges for extended 
length of stay 
Rosenthal, 
et al. 
(2003) 
Argentina $4, 888 ICU 
(medical/surgical 
and coronary) 
Extra charges for extended 
length of stay, and 
antibiotics 
Shannon et 
al. (2006) 
United 
States 
$26, 839 ICU 
(medical and 
coronary) 
Extra charges for length of 
stay, antibiotics, 
laboratory/diagnostic tests, 
related procedures, and non-
nursing healthcare labor 
Higuera et 
al. (2007) 
Mexico 
City 
$11,591 ICU Extra charges for extended 
length of stay and 
antibiotics 
Tarricone, 
et al. 
(2010) 
Italy €9,154 ICU 
(4 different 
specialty areas) 
Extra charges for extended 
length of stay, medications, 
supplies, lab tests, and care 
by an infection specialist 
Dal Forno 
et al. 
(2012) 
Brazil $89, 886 ICU Difference in mean total 
cost of care including extra 
length of stay and resources 
until hospital discharge 
Raschka, et 
al. 
(2013) 
Canada $19, 776 Inpatient 
(non-ICU) 
Charges for extended length 
of stay  
$= Dollars; €= Euros; $NT=New Taiwanese Dollars 
 
A basic tenet within modern microeconomic theory regards value synonymously 
with the price of a commodity (Nicholson & Snyder, 2012).  Cost factors in healthcare 
can be direct or indirect.  Arguably, value in healthcare transcends consumerism given 
the inability to appraise both human lives and diverse costs associated with affliction.  
Indirect costs such as suffering, loss of life, or missed opportunities are difficult to 
quantify in terms of infection outcomes.  Conceptualization of healthcare as a commodity 
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ensues as access and bottom lines inevitably converge.  Direct medical costs are defined 
by Santerre and Neun (2010) as charges to the payer for tests, exams, treatment, and 
provision of care etc.  Identifying direct medical charges for specific adverse outcomes 
can be useful in cost-benefit analysis and designing research.   
Canadian Cost Factors 
The Canadian healthcare insurance plan is a universal model designated by public 
authority and delivered on a non-profit basis (Health Canada, 2013).  The Canada Health 
Act (1985) stipulates that hospital services include: accommodation and meals, services 
by all personnel employed within the institution, laboratory/radiology/diagnostic 
procedures and interpretation, drugs, supplies, and preparations, medical equipment and 
surgical supplies, full operative procedures and care for all services deemed medically 
necessary for maintaining health.  Fees for treating adverse events are absorbed within 
departmental operating budgets.  Observational research of past events puts cost 
containment into perspective by conveying the capital benefits of preventing adverse 
events.  CRBSI (the independent variable of the study) incurs extra charges (dependent 
variable).  Beyond prolonged hospital stays, care for CRBSI may include additional 
medications, laboratory tests, diagnostic tests, specialty consultation, and supplies 
(O’Grady et al., 2011; Tarricone, Torbica, Franzetti, & Rosenthal 2010).  Quantifying 
how individual resources are being used to treat CRBSI allows for cost estimations 
within universal funding models that may influence administrative decisions.    
For the purposes of this study CRBSI is operationally defined as a diagnosed 
bloodstream infection when no other source is apparent and confirmed by comparative or 
paired blood culture results with a time to positivity of 120 minutes or greater and/or 
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threefold difference in microbial load (Mermel et al., 2009).  The dependent variable, 
charge, is operationally defined as the Canadian dollar value for allocated resources 
(including inpatient hospital bed and all associated inpatient care, medications, laboratory 
and diagnostic tests, supplies for line replacement, stay in the intensive care unit, and 
services of a specialty physician) required for treating a confirmed CRBSI.  
Research Questions 
The cost of a CRBSI in Canadian blood stem cell transplant recipients with a 
tunneled CVC has not been reported in the literature.  This study addressed the following 
questions.  Among Canadian blood stem cell transplant recipients with a long term 
tunneled triple lumen subclavian CVC: 
1. Is CRBSI associated with an extended hospital stay? 
2. What are the average extra charges for diagnosing and treating CRBSI? 
3. What is the average total charge for a single CRBSI? 
Methods 
Design 
 Expedited institutional review board (IRB) approval for the study with a waiver of 
consent was granted from both academic and health care institutions.  A retrospective 
case-control comparison analyzed healthcare spending between two groups.  The case 
group included records with documented incidents of CRBSI.  The comparison group 
included matched control records with no documented incidents of CRBSI.   
Sample/Setting 
 The study sample consisted of medical records of blood stem cell transplant 
recipients with a tunneled triple lumen subclavian CVC, treated in a single adult 
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Canadian blood stem cell transplant program between 2008 and 2013.  Inclusion criteria 
for both groups stipulated the use of a tunneled CVC, completion of transplant, and 
documented CVC removal, as well as a confirmed CRBSI for the case group.  One 
additional criterion for records in the control group stipulated no documented incidence 
of CRBSI.  Several exclusion criteria were applied to both groups in sample selection to 
eliminate potential cost influences.  Records indicating simultaneous use of vascular or 
invasive catheters, more than one isolated CRBSI, tunnel infection, and multiple 
transplants, were excluded.  Records indicating other line-associated complications 
(occlusion, thrombosis in the superior vena cava, and accidental displacement) were also 
excluded alongside records with no comparable control.  Selection generated 133 pairs 
for a final sample size of 266.       
Instruments 
 Data was coded into an electronic dataset designed specifically for the study as no 
existing instrument was identified.  Clinical records and financial documents sourced the 
data yield.  Base charges to the public payer for blood stem cell transplants, medical tests, 
hospital stays, intensive care stays, procedures, and specialty consult fees for the 2013 
fiscal year were used to measure direct charges.  Other monetary data for the 2013 fiscal 
year that were billed to the public payer were obtained through inpatient pharmacy 
inventory list that reports charges per dose of medications used and manufacturer contract 
pricing (confirmed by the manufacturer) for central venous catheters. 
 Procedure 
All records were de-identified for any personal information in accordance with 
ethics regulations.  Demographics, length of stay, and length of time each catheter was in 
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place were transcribed from electronic and hard copy records and recorded for both 
groups.  All positive blood culture results were reviewed to confirm CRBSI according to 
pre-set study criteria and assigned to the case group.  For case records, physician notes 
and medical orders were further catalogued for actual usage of resources specifically 
indicated for diagnosing and treating CRBSI.  Charges were tallied by frequency of use 
according to set Canadian dollar values billed to the public payer for the 2013 fiscal year 
in the following domains: (1) length of stays, (2) laboratory tests, (3) diagnostic tests, (4) 
medications, (5) fees for insured procedures or consultations by a specialist physician, (6) 
replacement catheters, and (7) length of stays in the intensive care unit due to CRBSI.  
Additional supplies for delivering treatment (i.e. intravenous sets, infusion bags, cold 
packs etc.) were included as part of the daily hospital fees that are covered by the 
inpatient nursing unit budget.   
Similar to other observational studies, case records were paired with controls to 
enhance comparability of groups.  Control criteria were applied for matching each case 
record to a counterpart in age (+/- five years), gender, and type of transplant (autologous 
or allogeneic), diagnosis, type of stem cells, and treatment protocol.  Controls were 
purposively selected for exact matches on four or more criteria.  The Statistical Package 
for the Social Sciences (SPSS) Version 21 was used for data analysis (International 
Business Machines Corporation, 2010).  The parameters for statistical significance were 
pre-set at α of .05 and β of .80.  Non-parametric tests were used to analyze data in 
violation of assumptions for statistical tests.   
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Results 
The final sample of 133 case-control pairs (n = 266) were subjected to 31,110 
catheter days (M 117, SD = 87.63).  Nineteen different treatment protocols were used for 
transplant conditioning.  Sample characteristics are summarized in Table 4.  Independent 
t tests show no significant differences in age or body mass index between groups.  
Although there were more males than females in the sample, the gender dispersion 
between groups was similar given non-significant Chi square results.  Chi square tests 
also did not indicate group differences in diagnosis, type of transplanted cells, or 
treatment between case and control groups.  
Table 4 
Demographic Comparisons Between Case and Control Groups 
Variable Descriptive Independent t Chi Square 
 (M, SD, %) t df p χ² df p 
 
Age M  50.56  ± 11.92  
-.180 
 
264 
 
.858 
   
BMI M  25.15 ± 5.54  
-.717 
 
264 
 
.474 
   
Gender 
Male 
Female 
 
159 (59.8%) 
107 (40.2%) 
    
.141 
 
1 
 
.803 
Diagnosis 
*Other 
Leukemia 
Lymphoma 
 
70 (26.3%) 
110 (41.4%) 
186 (32.3%) 
    
0 
 
2 
 
1 
Cell 
Allogeneic 
Autologous 
 
150 (56.4%) 
116 (43.6%) 
    
0 
 
1 
 
1 
Treatment     20.74 18 .255 
*Other malignancy or blood disorder requiring blood or marrow cell transplant 
  
 Table 5 lists the numerous different organisms that were detected in the case 
group.  Five cultures grew two different organisms, two cultures grew three different 
organisms, and one culture grew four different organisms.  Seventy of the organisms 
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were classified as gram stain positive, 74 gram stain negative, and one gram stain was 
unknown.  The most frequently occurring infections were Staphylococcus genus (n=42), 
Escherichia Coli (n=25), Klebsiella (n=17), and Streptococcus species (n=14).  
Table 5 
Cultured Organisms in Cases of CRBSI 
 One Two Three Four Total 
Abiotrophia Defectiva 
Acinetobacter 
Acinetobacter Baumanni 
Acinetobacter Hydrophillia 
Bacillus Cereus 
Brevibacterium 
Candida Kreusei 
Candida Paropsilosi 
Citrobacter Freundii (complex) 
Citrobacter Kosari 
Clostridium Septicum 
Coryneform 
Diplococci 
Escherichia Coli 
Escherichia Cloacae 
Enterobacter Aerugenosis 
Enterococcus 
Enterococcus Faecalis 
Enterococcus (VRE) 
Fusobacterium 
Granulicatella 
Haemophilus Influenza 
Haemophilus Parainfluenza 
Klebsiella Pneumoniae 
Klebsiella Oxytoca 
Leptotrichia Buccalis 
Moraxella Catarrhalis 
Pantoea Species 
Pseudomonas 
Pseudomonas Aerugenosa 
Pseudomonas Oryzihabitans 
Rhizobium Radiobacter 
Roseomonas 
Serratia Marcescens 
Staphylococcus 
Staphylococcus Aureus 
Staphylococcus Capnocytophagia 
Staphylococcus (CNS) 
Staphylococcus Ludguenesis 
Staphylococcus (MRSA) 
Staphylococcus (MSSA) 
Stenotrophomonas 
Streptococcus 
Streptococcus Group B 
Streptococcus Group G 
Streptococcus Mitis 
Streptococcus Viridians 
1 
2 
1 
1 
1 
1 
1 
1 
1 
1 
 
1 
1 
22 
5 
1 
 
2 
1 
1 
 
1 
1 
16 
1 
1 
1 
1 
2 
2 
1 
2 
1 
1 
2 
7 
1 
28 
2 
1 
 
2 
2 
4 
1 
6 
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1 
1 
1 
16 
1 
1 
1 
1 
3 
2 
1 
3 
1 
1 
2 
9 
1 
28 
2 
1 
1 
2 
2 
5 
1 
6 
1 
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 Control group records indicated 1,798 more catheter days than case group records 
with a mean difference of 13.51 days.  Case records also indicated line replacement with 
a tunneled catheter on 22 occasions, a percutaneous intravenous central catheter (PICC) 
on 33 occasions, and an intra-jugular (IJ) catheter on seven occasions for a total 
requirement of 62 new lines (46.62%).  Five records indicated ICU admission for 
infection.  Eight cases and nine controls indicated demise with a CVC in situ.   
 The majority of the sample (n=253) exceeded the base allotment of hospital days 
for transplant with two records indicating discharge as estimated, eight discharges one 
day early, and three discharges two days early.  Table 6 shows that inpatient length of 
stay ranged from 14-313 days.  Mann Whitney U tests show there were significant 
differences in length of hospital stay (U = 6456, z = 3.664, p = <.001 r = .22) and 
subsequent costs of hospital stay (U = 6319, z = 4.027, p = <.001, r = .23) between 
groups, with longer stay and higher expenses associated with the case group.  The case 
group stayed on average 19.81 days longer in the hospital than the control group.  
Table 6 
Catheter Days and Length of Stay in Case and Control Groups 
 Median Range SD Mean Difference 
Catheter Days 
Case 
Control 
Total 
 
83 
93 
92.5 
 
6-413 
18-424 
6-424 
 
93.16 
81.52 
87.63 
 
110.2 
123.71 
116.95 
 
 
13.51 days 
Length of Stay 
Case 
Control 
Total 
 
53 
39 
45.5 
 
15-313 
14-269 
14-313 
 
54.48 
52.08 
48.6 
 
71.89 
52.08 
61.99 
 
 
19.81 days 
 
 Results of a Mann Whitney U test also revealed significant differences in total 
charges between groups (U = 5759, z = 4.96, p<.001, r = .30).  The mean difference in 
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hospital stays of 19.81 days in the case group carried a price tag of $40, 986.89.  Extra 
charges for treating infection ranged from $70.60 to1$198, 993.63 with a mean extra 
charges totaling $4, 683.90 (Median $708.5, SD $23, 803.51).  The total estimated 
charges for a single infection considering fees for the mean extra length of stays and extra 
charges for actual resource usage were $45, 670.79. 
Discussion 
 Results from the case control study of CRBSI in a single Canadian blood stem 
cell transplant centre reveal significant cost implications to both the program and the 
patient.  Quality of life costs of CRBSI unmeasured by the current study deserve 
consideration.  While the centre must absorb charges of $45,670.79 on average, the 
patient costs of discomfort with line replacement, time spent away from loved ones while 
in the hospital, and the symptom experiences of infection, to name a few, may be valued 
by individuals beyond monetary worth.   
 CRBSI in the case group is associated with shortened catheter life which 
coincides with practice guidelines that recommend line removal depending on the overall 
clinical picture and with certain organisms (Mermel, 2009).  Studies comparing costs of 
salvaging lines versus replacement are needed to further inform practitioners in cost-
effective decision making.  Dibb et al. (2012) concur that removing a line on account of 
complications is not always necessary or possible as it may be needed for emergent 
rescue or may cause needless discomfort when simple treatments are possible.  The 
tunneled catheters used in the sample population are designed for long term use (>90 
days), and the mean length of use surpassed this time frame in both study groups (Joint 
Commission, 2012).  Maintaining the integrity of the line without infection is possible as 
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several cases and controls retained a CVC for a year or longer.  Care efforts should target 
prevention of infection over reactive management. 
 Although results indicate small effect size for the difference in length of stay 
between groups it was the most expensive charge.  Intrinsic risk, namely compromised 
immunity, may explain part of the additional hospitalization required in blood stem cell 
transplant.  However, in this study clear differences between groups make the case for 
inference that infection is also associated with prolonged stay in this population which 
coincides with past study findings (Dal Forno et al., 2012; Raschka, Dempster, & Bryce, 
2013).   
 Effect size increased when considering total charges for diagnosing and treating 
infection.  The need for intensive care support in five cases inflated the range of charges 
followed by medication use, and replacing the CVC.  The wide variation in total charges 
also reflects the complexity of care required in the blood stem cell transplant population, 
the nature of different organisms, and difficulty in predicting individual care needs.  
Nearly all (95%) of the sample exceeded allotted hospital days included in the base price 
of transplant which suggests program funding is grossly underestimated.   
 The abundance of different organisms responsible for CRBSI in the sample may 
explain part of the wide variance in charges for treating CRBSI.  Staphylococcus genus is 
the most widespread nosocomial pathogen within the study sample and globally (Bereket, 
2012).  Multi drug resistant gram negative organisms in the sample, such as 
Acinetobacter Baumanni, Stenotrophomonas Maltophilia and Pseudomonas, are known 
to have changing dynamics in cell function and the ability to resist current treatments 
(Bereket, 2012).  This study did not show increased treatment costs with more resistant 
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gram stain negative types of organisms; rather, four of the five cases were admitted to the 
ICU with gram positive Staphylococcus genus organisms (none of which were identical) 
and one case of a fungal infection.  Higher costs may be due to the onset of infection at a 
more vulnerable time in the treatment process.  The nadir of chemotherapy conditioning, 
graft versus host disease, prolonged neutropenia, or relapse/graft failure that were not 
controlled for within this study beyond matching cases and controls; however, length of 
stays and extra charges were observed to be higher with related donor transplants, 
followed by unrelated donor transplants and lastly, self-donations.   Cost analyses that 
distinguish infection outcomes and associated fees between allogeneic and autologous 
recipients are worth future research attention. 
In addition to limitations noted in the discussion above, retrospective observations 
limit the ability to isolate causal relationships.  Stringent matching criteria were 
implemented to offset validity threats by controlling group comparability.  A second 
factor not considered in the study was that records were not audited beyond line 
replacement with non-tunneled catheters.  Similar analyses with other catheter types have 
the potential to further inform practitioners on the best type of intravenous device to use 
post-transplant should tunneled CVC complications occur.  Indirect costs to patients and 
the system, and associated cost for symptom management on an as needed basis were 
also not measured in this study; however, it is more likely that these considerations would 
inflate rather than reduce the overall estimate.   
Summary 
Curtailing hospital infection is not a new issue in healthcare.  However, charges 
continue to inflate, outdating past cost-analyses.  This study found that in 2013, CRBSI in 
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a Canadian blood stem cell transplant centre increased resource allocation, shortened 
central venous catheter life by an average of 13.51 days, extended hospital stays an 
average of 19.81 days, and incurred average charges of  $45, 670.79 per incident.  It is 
reasonable to expect similar results across Canadian blood stem cell transplant programs 
and with other bloodstream infections with the exception of fees incurred for CVC 
replacement.  Costs may be lower in less acute areas and among populations that are not 
faced with immune system compromise. 
The relatively small stem cell transplant population is a large contributor to 
healthcare spending.  Reassessment of base funding in support of the program is needed 
alongside research targeting infection reduction.  Nursing studies examining practice 
strategies aimed at reducing thrombo-infective complications with CVC care may be 
invaluable assets to cost containment.  Findings from this study may be useful for 
estimating cost avoidance in research of clinical interventions that lead to a reduction in 
CRBSI and other device-associated bloodstream infections.   
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Chapter Four:  Analysis of Costs and Benefits of Tunneled Central Venous Catheter 
Dressings in Canadian Stem Cell Transplant Recipients 
Abstract 
Catheter-related bloodstream infection (CRBSI), an avoidable risk in cancer nursing, 
contributes to patient morbidity, and increases health care spending.  The objective of the 
study was to evaluate the impact of three different nursing care strategies for tunneled 
central venous catheter (CVC) exit sites on infection outcomes and compare costs of each 
strategy.  The study hypothesis proposed that CRBSI and charges for nursing care differ 
in Canadian blood and marrow cell transplant recipients with a tunneled CVC that use a 
transparent dressing, no dressing, or a gauze dressing.  A sample of 432 records at a 
single centre compared CRBSI between dressing groups.  A micro-costing approach was 
used to estimate dressing supply charges for an evaluation of the costs and benefits of 
each exit care strategy.  Results of the study indicated no significant differences in 
CRBSI, number of organisms, gram stain of organisms, development of infections before 
or after tunnel healing, or onset of infection between the three dressing groups.  In terms 
of supplies alone, transparent dressings were most economical, followed by no dressing 
and lastly, gauze.  The no dressing strategy was the most cost-effective alternative to 
using a transparent dressing.   
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Chapter Four:  Analysis of Costs and Benefits of Tunneled Central Venous Catheter 
Dressings in Canadian Stem Cell Transplant Recipients 
Infection control, essential in minimizing healthcare costs, continues to challenge 
healthcare providers.  Risk of infection is particularly concerning in blood stem cell 
transplant recipients given their weakened immune function and dependence on 
prolonged vascular access (Tomblyn et al., 2009).  Nearly all blood stem cell transplant 
patients receive a tunneled central venous catheter (CVC) to facilitate life-saving 
treatment as it poses the lowest infection risk of all long term catheter choices (Faruqi et 
al. 2012; Scales, 2010a; Toscano et al., 2009).  Catheter-related bloodstream infection 
(CRBSI) is typically associated with morbidity and expense rather than fatality (O’Grady 
et al., 2011).  Blood stem cell transplant nurses are influential in preventing CRBSI as 
they manage and educate others on CVC care.  Cost-benefit analysis considers how much 
and to what degree expected costs outweigh the total expected benefits (Santerre & Neun, 
2010).  Different care strategies do not posit equal expenditure.  The effects and charges 
to the public payer for various exit site care strategies performed by registered nurses on 
infection outcomes are unknown in Canadian blood stem cell transplant.   
A tunneled CVC features a cuff placed under the skin with the proximal end 
resting in the superior vena cava and a salient distal end (Scales, 2011).  Immediate 
placement of a sterile dressing after CVC insertion secures the device until the cuff 
embeds into the surrounding tissue (tunnel healing), and protects the puncture sites 
(Macklin, 2010; Poole, 2010; Scales, 2011).  Practice consultants such as the Infusion 
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Nurses Society (INS), claim a dressing on a healed CVC tunnel is unnecessary 
while others including the American Centers for Disease Control and Prevention (CDC) 
posit that they can make no recommendation on the issue (INS, 2011; Joint Commission, 
2012; O’Grady et al., 2011; Scales, 2010b; Toscano et al., 2009). 
Dressing options should meet patient needs and provide equal protection against 
infection risks.  Evidence of the clinical effectiveness of CVC exit site care in regards to 
CRBSI is limited.  The feasibility of certain nursing strategies must also be evaluated 
within the economic capacity of the financing system (Tarricone, Torbica, Franzetti, & 
Rosenthal, 2010).  Canadian CRBSI cost estimates (for all central venous catheter types) 
exceed $19,000 per incident (Raschka, Dempster, & Bryce, 2013).  A recent analysis by 
the author suggested CRBSI costs for Canadian blood stem cell transplant patients 
exceeded $45,000 per incident in 2013 (Keeler, in review).  Carefully weighing cost-to-
clinical benefit supports accountability in publicly funded healthcare.  Expected fees 
associated with adverse events and nursing care may strongly influence practice 
decisions.  The purpose of this study was to evaluate the impact on CRBSI and costs and 
benefits of nursing exit site care for Canadian blood stem cell transplant recipients with a 
long-term tunneled triple lumen subclavian CVC. 
Review of the Literature 
CRBSI 
CRBSI can develop from systemic microbes adhering to the catheter surface or 
the introduction of organisms on insertion, manipulation, or infusion (O’Grady et al., 
2011).  A primary bloodstream infection is deemed a CRBSI when an alternate source 
cannot be determined in a patient with a CVC in place for 48 hours or longer (Chopra, 
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Krein, Olmsted, Safdar, & Saint, 2013).  The most accurate diagnostic measure of CRBSI 
found by meta-analysis is paired blood cultures (Rodriguez et al., 2012).  The measure 
compares a CVC blood sample to a peripheral sample from the same individual.  Samples 
are grown in a media to detect and identify organisms.  Positive CVC results with 
negative peripheral results are strongly indicative of a catheter source of infection.  A 
difference in growth time-to-positivity between samples or three fold or greater microbial 
load in one sample also indicate the location of an infection (Mermel et al., 2009).  Paired 
blood cultures distinguish CRBSI from disease and treatment-related symptoms that a 
CVC was designed to manage (Macklin, 2010; O’Grady et al, 2011; Tomblyn et al, 
2009).   
Dressing   
  Popular CVC dressings are made of cotton fiber (gauze) or polyurethane 
(transparent).  A gauze dressing covers the exit site with or without securement.  The 
adhesive on one side of a transparent dressing attaches directly to the catheter and 
surrounding skin.  Dressings act as a barrier between the puncture site and the external 
environment.  Microbes naturally collect in the first five layers of the stratus corneum, 
hair follicles, and sebaceous glands, and can re-colonize within 48 hours of disinfecting  
necessitating dressing changes (Macklin, 2010).  Guidelines recommend changing a 
gauze dressing every two days and transparent dressing no more than once every seven 
days unless either is wet or soiled (O’Grady et al, 2011).     
The most recent Cochrane review reports a wide range of increased CRBSI with 
the use of transparent dressings, even while considering research bias (Gillies, 
O’Riordan, Sheriff, & Rickard, 2011).  Issues such as comparing different central line 
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types across different populations, lack of reporting effect size, lack of reporting missing 
data, and including overlapping variables are mentioned as result-limiting factors.  None 
of the research in the meta-analysis compared dressing types to undressed sites.  
Preliminary studies report that dressings are predictors of CRBSI in renal and intensive 
care populations compared to a no dressing group (Seiler & Pember, 2012; Toshiyuki et 
al. 2012).      
No Dressing 
The debate for maintaining a dressing on a healed CVC tunnel began with a pilot 
study reporting no difference in line infections in a small sample of cancer patients 
without exit site dressings (Petrasino, Becker, & Christiansen, 1988).  One random 
controlled trial by Olsin et al. (2004) revisited the issue.  However, the small sample and 
early closure requires additional evidence to support practice recommendations based on 
study findings.  This current state of the science contributes to questionable evidence 
guiding nursing care as approximately 40% of Canadian blood stem cell transplant 
centres reported in 2013 that their policy is to remove the dressing from a healed tunneled 
CVC site (Keeler, 2014).    
Additional Care Strategies 
Alternatives for preventing CRBSI can be found in the literature.  Applying honey 
to the exit site has not been reported to significantly reduce CRBSI (Kwakman et al., 
2012).  More popular is trialing medical products and antiseptic solutions with varying 
reports of significance (O’Grady et al., 2011; Popovich, Hova, Hayes, Weinstein, & 
Hayden, 2010).  Antibiotic ointment under the dressing in the blood stem cell transplant 
population is counterproductive as it is known to increase drug resistance and 
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colonization of fungi in immune compromised hosts (O’Grady et al., 2011; Tomblyn et 
al., 2009).  Allergies, skin toxicities, and age younger than two months may render use of 
adhesive and antiseptic patch dressings inapplicable (Battistella, Bhola & Lok, 2011; 
Daniels & Frei, 2012; Tomblyn et al., 2009).  Antimicrobial coated lines and impregnated 
cuffs are now available (Bard, 2012a; Bard, 2012b).  Practice consultants only 
recommend use of these products if all other prevention efforts fail to decrease CRBSI 
incidence (O’Grady et al., 2011).   
Theory 
Duval (2010) summarizes the evolution of Lister’s 19th century theory of asepsis 
that continues to guide clinical practice and research today.  The theory outlines human 
and animal coexistence with microorganisms that may be innocuous or cause illness.  
Pathological transfer of microorganisms can be prevented by natural immunity, 
inoculation, interrupting the cycle of transmission, or decreasing microbial load. 
Application of the theory has evolved into common reference to the principles of asepsis 
that are modeled in Figure 1.  Conformity to aseptic principles incorporates preventing 
exposure and/or any activities or techniques that aim to decrease or eliminate microbial 
presence.  Examples include avoiding contact, inoculation, maintaining a dry 
environment, or using products and strategies for sanitization, disinfection, or 
sterilization (Lister, as cited by Beck, 1895; Macklin, 2010; Medeiros, dos Santos, 
Soares, Costa, & Lira, 2012; Pallo, 2012; Scales, 2011).   
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Figure 1.  Model of Lister’s Asepsis Theory 
Judgment is required for applying aseptic principles in clinical care.  For example, 
the aim of inoculation is exposure to certain organisms to stimulate an immune response 
should repeat exposure occur.  Infection prevention strategies are multifaceted depending 
on clinical context and body of epidemiological knowledge.  Avoiding infection requires 
conscious multidisciplinary efforts and actions at all stages of care and treatment in blood 
stem cell transplant.   
Variable Selection 
Study variables were selected after consideration of all other strategies 
incorporating aseptic principles with CVC access already in place at the study centre.  
The bundling strategy is used for catheter insertion.  This strategy includes proper hand 
hygiene, using maximum barrier precautions (sterile gown, drape, gloves, equipment, and 
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wearing a mask), using a >0.5% chlorhexidine skin prep solution, choosing the 
appropriate site if known and a daily review of the necessity of the catheter with prompt 
removal when no longer essential (Faruqi et al., 2012; Moreau, 2009).  In addition to the 
bundle strategy for insertion, all catheters are placed by a radiologist under ultrasound 
guidance.   
Policy and nursing standard operating procedures at the study site mandate nearly 
all CDC recommendations for CVC practice and incorporate several principles of asepsis.  
Initial and yearly education for CVC competency is required in accordance with program 
accreditation standards.  The support of both clinical nurse educators and experienced 
clinicians is available for staff skill certification and troubleshooting catheter-related 
complications.  Prior to delegating the task, registered nurses assess patients’ and lay 
caregivers’ competency with exit site care by return demonstration.  CVC access, 
infusions, and manipulations are performed via a needleless luer piggyback system with 
replacement of all infusion sets every 24 hours if the system is interrupted and every 72 
hours if the system is uninterrupted.  Sterile technique is mandated for dressing and cap 
changes with use of a sterile mask, gloves, and supplies, and 2% chlorhexidine skin 
antiseptic.  Hand hygiene is routinely audited by the infection prevention and control 
department, and standard operating procedure mandates an alcohol scrub-the-hub for 15 
seconds strategy for sterilizing connections prior to accessing infusion ports.   
A policy change in 2011 incorporated removing the dressing from healed 
tunneled exit site and use of protective coverings over puncture sites and connections 
during showering.  Prior to the current policy, transparent dressings were used when 
adhesive was tolerated; gauze dressings were used for individuals with skin sensitivities.  
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After the policy change all patients were instructed to remove the dressing after tunnel 
healing.   
In spite of adherence to CDC guidelines and asepsis, CRBSI still occurs.  
According to the Institute for Healthcare Improvement (IHI), a CRBSI is criterion based 
infection diagnosed when no other source is apparent (2013).  Confirmation that an 
infection is related to a CVC is obtained through comparative blood cultures.  The 
Canadian Nosocomial Infection Surveillance Program (CNISP) criteria (2005) were used 
to operationally define CRBSI as the dependent variable for the study.  The independent 
variable was the type of exit site care provided for a tunneled CVC at three levels: 
transparent dressing, no dressing after tunnel healing, or gauze dressing.  The literature 
revealed a gap in the evidence regarding dressing maintenance after tunnel healing which 
generated the study hypothesis that there are differences in CRBSI and charges for exit 
site care strategies for Canadian blood stem cell transplant recipients with a long term 
tunneled triple lumen subclavian CVC that use a transparent dressing, no dressing, or 
gauze dressing.   
Methods 
Design 
 Following study approval by institutional and health board ethics committees, 
archived data from a single Canadian transplant centre was accessed.  The posttest-only 
control group design was used to compare the dependent variable (CRBSI) after a 
specific treatment condition (type of dressing) among groups.  A micro-costing approach 
was used to estimate the charges to the public payer for using a transparent dressing, no 
dressing, or gauze dressing, according to supplies and frequency of care.   
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Sample/Setting 
 The clinical records of adult blood and marrow cell transplant recipients from a 
single Canadian centre treated between 2008 and 2013 were reviewed.  Documents 
noting completion of blood and/or marrow cell transplant and use of a long term tunneled 
cuffed triple lumen subclavian CVC were included in the sample.  Records with absent 
documentation for line removal were excluded alongside records indicating catheters still 
in place.  Additional exclusion criteria included known source of infection, multiple 
catheters at once, and non-adherence to standard policy and procedure for exit site care.  
All eligible records indicating dressing removal after tunnel healing were included in the 
sample.  A purposive sample of records indicating the use of a gauze dressing or use of a 
transparent dressing were randomly selected until all three groups were equal in number.  
The transparent group (the largest group overall) was further stratified until overall 
gender dispersion was similar (N=432).   
Instruments 
 Blood culture results were interpreted and confirmed using federal surveillance 
standards for reporting hospital acquired infections and practice recommendations from 
the Infectious Diseases Society of America (CNISP, 2005; Mermel et al., 2009).  
Electronic flow sheets and multidisciplinary progress notes were consulted to confirm 
individual dressing strategies.  Nursing CVC policy and procedure and inventory price 
lists for supplies were used as measures for estimating weekly charges for each dressing 
strategy.  
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Procedure 
Study data was de-identified and converted to an electronic data set.  Analysis 
was performed using the Statistical Package for the Social Sciences (SPSS) Version 21 
(International Business Machines Corporation, 2012).  An inventory list indicating prices 
for supplies that were billed to the public payer by the inpatient blood stem cell transplant 
nursing unit was accessed.  Charges for all supplies listed in the nursing policy and 
procedure document and unit standard operating procedures were tallied according to 
dressing strategy: for example, gloves, chlorhexidine swab sticks, dressing type, shower 
covers etc.  Weekly costs were determined according to policy with transparent dressings 
changed after seven days, daily care after showering for the no dressing group, and gauze 
dressings changed after 48 hours.  Individual dressing costs were estimated by 
multiplying the weekly cost of the dressing strategy used by the number of weeks the 
catheter was in place.  Individual costs were adjusted for use of securement devices (once 
a week) and initial care post insertion (mean cost for the no dressing groups until tunnel 
healing set at day 14).  Parameters for statistical significance were set at α at .05 and β at 
.80.  The analysis of variance test was used to compare differences in CRBSI between 
groups.  Kruskall-Wallis tests were used to analyze data in violation of assumptions for 
parametric statistics, and the Chi square test was used to analyze categorical data.   
Results 
 The final sample represented 46,496 catheter days (M 107.63, SD 74.86) for 432 
recipients of allogeneic (46.53%), autologous (53.01%), and syngeneic (.46%) blood 
and/or marrow cell transplant.  Overall, Table 7 shows there were similar numbers of 
males and females in the entire sample; however, dressing dispersion by gender was not 
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equal.  Analysis of variance tests were non-significant when comparing groups according 
to age F (2) = .489, p = .614, and body mass index F (2) = 2.849, p = .059.  Chi square 
results also showed no significant differences in general diagnosis between groups, χ² (4) 
= 5.884, p = .208.   
Table 7 
Study Sample Characteristics and Catheter History 
  
 
Transparent 
Dressing 
No  
Dressing 
Gauze Dressing Total 
(N=432) 
Male 
Female 
42 
102 
93 
51 
78 
66 
213 
219 
Age 49.65±13.34 51.15±12.95 50.19±12.79 50.33±13.01 
BMI 24.51±5.11 25.54±4.8 25.92±5.58 25.32±5.19 
Leukemia 
Lymphoma 
Other 
53 (36.8%) 
46 (31.94%) 
45 (31.25%) 
40 (27.78%) 
48 (33.33%) 
56 (38.89%) 
53 (36.8%) 
52 (36.11%) 
39 (27.08%) 
146 (32.4%) 
146 (33.8%) 
140 (33.8%) 
Allogeneic 
Autologous 
Syngeneic 
72 (50%) 
72 (50%) 
0 
55 (38.2%) 
88 (61.1%) 
1 (.7%) 
74 (51.4%) 
69 (47.9%) 
1 (.7%) 
201 (46.5%) 
229 (53%) 
2 (.5%) 
Catheter Days 
            M, SD 
16966 
117.82±70.54 
14116 
98.03±62.79 
15414 
107.04±88.17 
46496 
107.63±74.86 
Infections 52 43 52 147 
Incidence 12.04% 9.95% 12.04% 34% 
*Prevalence 3.06 3.04 3.37 3.16 
Other= disease or malignancy treated with blood stem cell transplant 
*Prevalence = number of infections per 1000 catheter days 
 
 All records indicated treatment with a conditioning chemotherapy protocol 
followed by a blood stem cell transplant.  Of the 432 patients, 129 individuals developed 
147 separate CRBSIs (113 people with one infection, 14 people with two infections, and 
two people with three infections).  Multiple infections that met the criteria for being a 
new infection were included in the analysis for a total incidence of 34% and prevalence 
rate of 3.16 infections per 1000 catheter days.  CVC replacement due to infection was 
required in 70 cases (16.2%) and one record indicated demise was suspected from a 
CRBSI.  
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 The lowest incidence rate for the no dressing group and highest prevalence rate 
for the gauze dressing group indicated on Table 7 reveal there are slight differences in 
infection outcomes according to dressing group.   Comparative statistical tests in Table 8, 
however, show that the differences between infection groups are non-significant.  
Table 8 
Infection Among Dressing Groups 
 Analysis of Variance Kruskall-Wallis Chi Square 
 F df p ω H p χ ² p 
       
CRBSI .375 (2,429) .555 .05     
Number of 
Organisms 
.700 (2,429) .497 .06     
Gram + 
Organisms 
1.104 (2,429) .333 .07     
Gram - 
Organisms 
.396 (2,429) .673 .04     
Onset of 
First 
Infection 
1.779 (2,429) .17 .09     
Onset of 
Second 
Infection 
.285 (2,429) .752 .04     
Onset of 
Third 
Infection 
    2 1   
Stage of 
Tunnel 
Healing 
      6.558 .34 
 
Analysis of variance results indicate there were no significant differences in the number 
of infections, number of organisms, gram stain of organisms, or onset of infection among 
groups.  According to Field (2009) ω calculations more accurately estimates effect size 
beyond the sample population because average variance is considered rather than using 
numerator sum of squares of the model over denominator total sum of squares.  The ω 
values in Table 8 indicate that the average variance explained by the analysis of variance 
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tests are minute, coinciding with non-significant findings of difference between groups.  
There were also no significant differences in the number of infections before tunnel 
healing (day 14), or after tunnel healing (day 15 and beyond) among groups as indicated 
by the non-significant results of the χ² test. 
 Although overall effects of type of dressing on CRBSI are small, between group 
comparisons in Table 9 reveal odds ratios (OR) and relative risks (RR) were higher in the 
gauze and transparent groups than the no dressing group, with gauze and transparent 
dressings resulting in equal risk.  OR was determined by dividing the odds of developing 
an infection in one group by the odds of developing infection in a different group.  
Similarly, RR was determined by dividing the percentage of infection in one group by the 
percentage of infection in a different group.  The odds of developing an infection in the 
gauze group were .58 times higher than the no dressing group.  The odds of developing 
and infection in the transparent group were also higher than the no dressing group by .25.  
Relative risks for each group comparison show narrower differences between each 
dressing group with a .21% higher risk when a gauze dressing versus no dressing is used, 
and a .17 % higher risk of infection when a transparent dressing is used instead of no 
dressing.   
 The abnormally distributed cost variables were analyzed with non-parametric 
equivalent tests, namely the Chi square test for multiple group comparisons, and the 
Mann Whitney U test was used in substitute of a parametric t test.  There were significant 
differences in costs of each care strategy, χ ² = 2.75.68 (df2), p <.001.  Mann Whitney U 
tests show gauze dressings (M $2059.7, SD 1660.81) cost more than no dressing (M 
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$712.31, SD 501.312), and no dressing costs more than using a transparent dressing (M 
$445.8, SD 682.32). 
Table 9 
CRBSI Risk and Cost Differences Between Dressing Strategies 
CRBSI Cost 
 Odds 
Ratio 
Relative 
Risk 
Mann Whitney 
 OR RR U z p r 
GD vs. ND 1.33 1.21 3784 9.32 <.001 .55 
GD vs. TD 1 1 1787 12.14 <.001 .72 
ND vs.TD .75 .83 5381 7.06 <.001 .42 
GD=gauze dressing, ND=no dressing, TD=transparent dressing 
 
Discussion 
 Results from this study comparing the incidence of CRBSI among blood stem cell 
transplant recipients whose tunneled catheter sites were managed with either gauze, 
transparent, or no dressing suggest that the type of CVC exit site dressing is not 
associated with infection in this population.  However, supply charges for the different 
dressing strategies were significantly different, with gauze dressings incurring the highest 
costs to maintain ($ 59.10/week), followed by  no dressings ($55.89/week), and lastly, 
transparent dressings ($23.71/week).   The overall costs and benefits of each strategy 
require clinical judgment and consideration of negative outcomes, charges, and non-
monetary costs.   
 Study results indicate bloodstream contamination at the tunnel site is unlikely 
when the site is kept dry beneath dressings or by dressing removal.  Initial dressings 
prevent exposure to host bodily fluids and catheter slippage until the tunnel site has 
healed.  O’Grady et al. (2011) suggest moisture catalyzes microbial tunnel migration and 
increases surface colonization thereby advising to protect access sites from unsterile 
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precipitation.  Recommendations are based on case-reports of water borne infections 
likely introduced via unprotected connections.  Covering all sites and connections during 
showering may be more influential on CRBSI reduction than the type of dressing.   
 It is further advised to use careful judgment with dressing maintenance for a 
prolonged period of time (O’Grady et al., 2011).  Clinical judgment is also needed for 
dressing removal.  Daily skin antisepsis, shower covers and using securement devices are 
recommended strategies that incur charges.  Medical products designed for these 
purposes may not be feasible in low income countries or may be intentionally overused in 
for-profit areas.  All patients should receive equal quality and commission of essential 
health care.  Affordable options such as using cellophane and waterproof tape may be 
viable solutions to overcoming the expense of using brand name medical products 
without reducing care quality.  In addition, like dressings, some patients may not tolerate 
adhesive shower coverings and securement devices.  Topical skin barriers and/or 
hydrocolloid dressings in conjunction with adhesive should be used with discretion over 
removing the dressing entirely. 
It appears the recent trend to remove the dressing from a healed tunneled exit site 
is not only a safe strategy it is also a cost-effective alternative to using a gauze dressing in 
terms of supply charges.  In accordance with asepsis theory, the embedded cuff suffices 
as a barrier while removing the dressing maintains a dry environment.  Daily skin 
cleansing with the no dressing strategy also ensures more frequent attempts to reduce 
microbial load around the exit site.  However, daily skin antisepsis after showering as 
opposed to cleansing once per week incurs fees for supplies that exceed the more 
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traditional approach of using a transparent dressing.  Options at the bedside should 
consider additional potential factors that inflate expenses when treatment is lengthy.     
 A recent survey of Canadian CVC practice in blood stem cell transplant reports 
registered nurses spend up to 30 minutes for a single dressing change with average time 
of 15 minutes (Keeler, 2014).  A review of collective agreements for nursing wages in 
Canada in 2013 (Table 10), reveals that the national average hourly wage for a level I 
registered nurse (excluding the Territories and Quebec) is $35.28.  The gauze dressing 
strategy incurs more than double the expense of a transparent dressing when considering 
nursing wages that do not need to be factored into the costs of the no dressing strategy.  
Removing the dressing from a healed tunneled CVC site can reduce time constraints on 
registered nurses that perform dressing change procedures and educate others so the task 
can be delegated. 
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Table 10 
Average Canadian 2013 Registered Nursing Wages 
Increment BC AB SK MB ON NB NS PEI NFLD 
1 30.79 35.00 34.94 31.02 30.17 29.86 32.84 29.57 30.77 
2 31.96 36.34 36.59 32.10 30.91 31.87 33.82 30.77 31.98 
3 33.16 37.69 37.43 33.19 31.12 33.05 34.91 32.16 33.28 
4 34.33 39.04 38.28 34.32 32.65 34.42 36.13 33.53 34.88 
5 35.52 40.39 39.19 35.428 34.2 35.76 37.39 34.91 36.46 
6 36.71 41.72 40.09 36.572 36.12 36.80 38.69 36.03 38.10 
7 37.90 43.08 41.45 - 38.06 37.88 - - - 
8 39.02 44.35 42.81 - 40.01 - - - - 
9 40.42 45.93 44.08 - 42.85 - - - - 
Average 31.04 40.39 39.43 33.77 35.94 34.23 35.63 32.82 34.25 
National Average 35.28 
*Excluding QC and the Territories 
* For level I registered nurses excluding education/shift/weekend/long-service differentials, or retrospective lump sum payments 
 
 Patient context may be the most important factor in determining the type of CVC 
exit site care required.  Typically, individuals with allergies to adhesive employ the use of 
a gauze dressing.  Dressing removal may also serve as a more comfortable option to other 
individuals by eliminating pruritus and decreasing excoriation from repeat adhesive 
removal.  Findings from this study suggest that resorting to no dressing is a more cost-
effective approach than using gauze.  Dressing removal may also relieve care burden on 
patients and lay caregivers by simplifying the amount of education needed and 
minimizing the number of tasks required for self-care.  Cost savings should be balanced 
with patient preference and provider experience when implementing nursing policy.    
 It was noted that adherence to the policy of removing the dressing was not rapidly 
incorporated at the study site.  Clinical documentation indicated some patients were 
anxious and/or uncomfortable leaving the exit site open to air.  Non-adherence to 
removing the dressing after the policy change could have result-limiting effects.  
Individuals who refused the no-dressing strategy were eligible to be included in the 
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sample.  It is unclear if individual choice increases vigilance with infection prevention; 
however, results do not indicate significant infection reduction in groups that used 
dressings.   
Conclusion 
The decision to dress and maintain a CVC dressing is the responsibility of 
clinicians who employ best practices based on empirical evidence, clinical expertise, and 
patient preference.  Differences in nursing care strategies are not necessarily disparities.  
Rather the various care approaches may represent conscious efforts of nurses applying 
theoretical and practice-based experience at the bedside.  The study empirically supports 
each dressing strategy in terms of infection risk while weighing in on certain costs and 
benefits.  Overall, this study supports the traditional use of transparent dressings on a 
tunneled CVC in the blood stem cell transplant population unless circumstances dictate 
intolerance.  The no dressing strategy is the recommended alternative to a transparent 
dressing as it is a safe and more cost-effective approach than using gauze dressings.  
Further cost containment can be achieved with the no dressing strategy by reducing time 
constraints on nurses and patients that are difficult to quantify in monetary measures.   
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Chapter Five:  Summary 
 Registered nursing is a theoretically based science that involves application of 
experience, skills, and evidence-based interventions.  Nurses are not as interchangeable 
between practice settings as their historic counterparts.  Specialty areas require 
competencies that were once viewed as advanced practice.  The evolution of healthcare 
has pushed nursing research to examine specific gaps in evidence within specific 
populations and specific circumstances.  This research approach not only assists in 
controlling construct validity; it also fine tunes nursing science and confirms theoretical 
standpoints for care strategies that have not been empirically tested.   
 Blood and marrow cell transplant nursing is a unique practice specialty with its 
own nursing subculture.  Nurses in this area have first-hand familiarity with common 
morbidities associated with cancer treatment.  Leung et al. (2012), report that bone 
marrow transplant nurses in Canada undergo immense stress when they know their 
patients are suffering.  The interpersonal element of care gives rise to leadership and 
advocacy at the bedside that can be critical to patient well-being.  When nursing practice 
changes are imposed with little support, the professionals expected to deliver care may 
question quality measures.  In turn, administrators may be faced with lack of adherence to 
policy.  Légaré et al. (2010) also point out the importance of shared decision-making that 
maintains the patient as the centre focus and incorporates family and significant others.  
The model includes the client as a key stakeholder in inter-professional collaboration and 
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mitigates barriers to the most appropriate plan of care for an individual.  It is essential 
that policy decisions include input from frontline personnel and be communicated with 
credible evidence to achieve a buy in for change; especially when the ramifications for 
practice are life threatening and expensive.  Building organizational rapport may also 
indirectly influence bedside rapport and patient satisfaction with care recommendations.   
 The general topic addressed by this research project involved clinical changes to 
CVC care practice with blood and marrow cell transplant recipients.  Guiding evidence to 
support these actions was conflicting and/or absent in the literature.  It was first 
established through a descriptive survey that CVC practice differs across Canada; 
however, the individual needs of each patient were considered to be a primary 
consideration when selecting an exit site care strategy for a tunneled CVC.  Other 
discrepancies such as different competency training approaches and flushing protocols 
are worth future nursing research attention.  Blanketing strategies across the entire blood 
stem cell transplant population undermines the flexibility and judgment of unique 
circumstances in registered nursing.  Differences in care do not constitute disparity; 
rather, they provide options that require expertise for selection.   
 Awareness of the cost implications for nursing care strategies may assist the 
organization in capital planning.  The study estimating the cost of CRBSI in blood and 
marrow cell transplant recipients with a tunneled triple lumen subclavian CVC was 
conducted with the intent to highlight the importance of infection prevention.  Findings 
revealed significant healthcare expenses in the presence of CRBSI within the blood stem 
cell transplant population which are higher than infection costs in other clinical areas.  
Budgets should not dictate clinical decisions that favor administrative goals over patient 
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outcomes.   Abuse of this knowledge has the potential to violate the trust of both 
consumers and clinicians alike.  Insights into the costs of negative outcomes should be 
used for targeting prevention strategies that maintain patient-focused quality care.  In 
turn, solutions can serve multifaceted purposes that meet the goals of all parties involved 
in the healthcare system.   
 The third study compared the no-dressing strategy that was the subject of a 
practice change initiated at a large transplant center in Canada to two other dressing 
alternatives for patients with tunneled catheters who received blood stem cell transplant.  
Findings were able to substantiate all three care approaches in terms of infection risks.  
Results fill the gap in the evidence for recommending removing the dressing from a 
healed tunneled CVC exit site.  Analysis of the costs and benefits of each strategy may 
further inform practice decisions at bedside and administrative levels.  Nursing care of 
the exit site did not positively influence infection outcomes provided all other current 
guidelines are followed.  Additional research investigation of other areas of nursing 
influence may further elucidate unknown sources of CRBSI. 
 Findings from all three studies have the potential to influence stem cell nursing 
practice in Canada and across the globe.  Further analysis of the large data set generated 
in this project is planned to delineate other areas of nursing influence on long-term 
tunneled triple lumen subclavian CVC-related complications.  Specific attention will be 
given to other complications noted in data collection such as occlusion and thrombosis in 
the superior vena cava, accidental line removal, and tunnel infection.  A more 
comprehensive analysis of specific organisms and gram staining will also be considered.  
Future research efforts will continue to focus on generating evidence to support practice 
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decisions for care of patients receiving stem cell transplants for hematologic disorders 
and malignancies.  
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Appendix A 
Survey 
Cover Letter 
Dear Participant 
Due to your experience, you have been selected to participate in a research study on 
central venous catheter practice in Canadian cell transplant.  Your perspective will help 
inform health policy and future research.  This study is being conducted by a Canadian 
doctoral candidate studying at the University of Texas at Tyler. 
 
A link to an attached survey is provided at the end of this document.  Participation 
assumes your consent.  You will receive an e-mail reminder of the survey if you are 
unable to participate at this time.  Results of your survey will be compared to other 
Canadian transplant centres.  The information you provide will be summarized and 
reported within a nursing doctoral dissertation and potentially a peer reviewed academic 
journal.   
 
You are free to ask questions or discuss participation at any time.  You are also free to 
withdraw at any time without prejudice.  Participants will be entered to win a random 
draw for a $50 Tim Horton’s gift card.  For information or questions feel free to contact 
Melanie Keeler at (403) 890-9249 or mkeeler@patriots.uttyler.edu 
 
This study has been approved by the Institutional Review Board at the University of 
Texas at Tyler.
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Appendix A (Continued) 
Survey Questions 
Demographic Questions 
1. In what Canadian Province or territory is your centre located? 
YT   NT   NU   BC   AB   SK   MB   ON   QC   NB   NS   NL   PEI    
2. Does your centre provide any of the following transplants (check all that apply) 
 
blood cell 
bone marrow 
cord 
hematopoietic progenitor stem cell   
  
 
3. What is the estimated number of transplant patients treated at your centre each 
year? 
 
 50 or less 50 to 100 more than 100 
4. Is your centre considered 
A) Adult 
B) Pediatric 
C) Both 
 
Content Questions 
The following section concerns central line education 
5. Does your centre have a policy in place to educate clinicians about central lines? 
 Insertion   Yes  No 
 Routine Care  Yes      No 
 Maintenance   Yes No 
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6. Does your centre have a policy in place to educate patients, family, or lay 
caregivers about central lines?  
 
 Routine Care  Yes No 
 Maintenance  Yes No 
 
7. How often is education on central line care reinforced at your centre for example, 
recertification, lunch and learn, or training modules? 
 
 Never  Yearly  Other______ 
 
The following section concerns the insertion of central lines at your centre 
 
8. Who is responsible for inserting central lines (excluding PICCS) at your centre? 
 
Radiologist/Radiology Resident 
Physician/Resident Physician 
Anesthesiologist 
Specialty Nurse 
Other (specify)_____ 
 
9. Where are non-emergent central lines inserted at your centre? 
 
Bedside 
Radiology department 
Operating room 
Angio suite 
Other (specify)_____ 
 
10. Select the barrier precautions used at your centre for central line insertion?  
 (Check all that apply) 
   
Hand washing 
Sterile field/drape/gown 
Aseptic technique 
Antiseptic skin preparation 
Mask 
Sterile glove 
Clean glove 
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11. What type of antiseptic solution is used for central line insertion at your centre? 
 
Unknown  
0.5% chlorhexidine 
2% chlorhexidine  
Tincture of Iodine  
Iodophor 
70% Alcohol 
Other (specify)_____ 
 
12. What type of central line is preferred and/or most commonly used for cell 
transplant recipients at your centre? 
 
  Tunneled 
Non-tunneled     
Port/IVAD     
IJ 
Femoral 
PICC     
Other (specify)_____ 
 
13. Does your centre use ultrasound guidance for central line insertion (excluding 
PICC)? 
 
Always When possible Never  Unknown 
 
14. How many lumens do the majority of central lines have in cell transplant 
recipients at your centre? 
 
1 
2 
3 
More than 3 
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15. Does your centre use central lines impregnated with antimicrobial agents? 
 
Yes Line 
Yes cuff and line 
No 
Unknown 
16. Do cell transplant recipients at your centre receive prophylactic antibiotics prior 
to line insertion? 
 
Yes 
No 
Unknown 
 
17. Is there a preferred insertion site for central line catheters in cell transplant 
recipients at your centre? 
 
Physician preference 
No 
Right subclavian 
Left subclavian 
Right IJ 
Left IJ 
Right Port/IVAD 
Left Port/IVAD 
Double lumen Port/IVAD 
Right Femoral 
Left Femoral 
Right PICC 
Left PICC 
 
The following section concerns central line maintenance at your centre 
 
18. What solution is used with central line catheters (excluding PICCS) at your 
centre? 
 
Not applicable 
Flushing solution______    Volume (mL)______ 
Locking solution______   Volume (mL)______ 
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19. Does your centre instill any of the following solutions into the lumen of an 
infected central line or when a central line infection is suspected? (check all that 
apply) 
 
No 
Sodium citrate 
Ethyl Alcohol 
Vancomycin 
Gentamyacin 
Other (specify)_____ 
 
20. Does your centre use any solutions with occluded or suspected central line 
occlusion? 
 
No 
High dose heparin (5000u/mL or >) 
Alteplase/Tpa 
Other (specify)_____ 
 
The following section concerns central line care at your centre 
 
21. What type of dressing is applied to a central line at your centre immediately after 
insertion? 
 
Pressure 
Gauze 
Gauze and transparent 
Mepore/Premapore 
Other (specify)_____ 
 
22. At what point after insertion is the initial dressing changed for a central venous 
catheter (excluding PICC)? 
 
24 hours or earlier if soiled 
48 hours 
1 week 
Other (specify)_____ 
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23. What type of dressing is most commonly applied to a central line when the initial 
dressing is removed? 
   
Gauze (with or without disc) 
Semi-transparent film such as tegaderm 
Mepore/Primapore 
Biopatch or chlorhexidine sponge 
Other (specify)___ 
 
24. How often is a non-soiled central line dressing changed at your centre? 
 
Daily 
Every 48 hours 
Weekly 
No more than once every 7 days 
Other (specify)_____ 
 
25. What is the average amount of time spent by you or a staff member for one 
central line dressing change? 
 
<15 minutes 15-30 minutes  30-45 minutes  45 minutes or 
more 
 
26. Does your centre maintain a dressing on a healed tunneled central line exit site? 
 
Yes  No 
 
27. Who performs central line dressing changes at your centre? (check all that apply) 
 
Physician 
Nurse Practitioner/Clinical Nurse Specialist 
Registered Nurse 
Licensed Practical Nurse 
Patient 
Family Member 
Lay caregiver 
Other (specify)_____ 
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28. What barriers/ precautions are used at your centre for central line dressings by 
staff at your centre? (check all that apply) 
 
Mask 
Sterile gown 
Sterile gloves 
Clean gloves 
Sterile drape 
0.5% chlorhexidine 
2% chlorhexidine 
Iodaphor 
Tincture of iodine 
70% alcohol 
Alcohol swabs 
Normal saline 
Other (specify)_____ 
 
29. At your centre, do cell transplant recipients with central lines use additional 
barriers or coverings such as aquaguard while showering? 
   
No 
Yes at all times and with all dressing types 
For gauze dressings only 
For healed tunneled lines open to air only 
Other (specify) 
 
30. How often is exit site skin care performed on central lines that do NOT have a 
dressing?  
 
Not applicable 
Daily 
More than once a day 
Only after showering 
Other (specify) 
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The following section deals with central line removal at your centre 
 
31. Who is responsible for removing central lines (excluding PICC) at your centre? 
 
Anesthesiologist 
Physician/Resident physician 
Advanced practice nurse 
Registered Nurse 
Anyone trained in the procedure 
Other (specify)______ 
 
32. Are central lines in cell transplant recipients promptly removed at your centre 
when no longer essential? 
   
Yes  No 
 
33. Under what circumstances would a cell transplant recipient have a central line 
replaced at your centre? (check all that apply) 
 
Suspect infection 
Known infection 
Suspect occlusion/thrombus 
Known occlusion/thrombus 
Malfunction 
Other (specify)_____ 
 
Thank you for your time and participation.  If you wish to be informed of the survey 
results please provide your contact information and preferred method of communication.  
This information will be stored in confidence and securely destroyed after results have 
been shared with you.   
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Institutional Review Board Approvals 
The University of Texas at Tyler 
Institutional Review Board 
 
October 10, 2013 
 
Dear Ms Keeler, 
 
Your request to conduct the study:  Cost-benefit Analysis of Tunneled Central Venous 
Catheter Dressings in Canadian Stem Cell Transplant Recipients IRB #F2013-17 has 
been approved by The University of Texas at Tyler Institutional Review Board under 
expedited review. This approval includes a waiver of written informed consent, and 
is conditional on approval by the Alberta Cancer Research Ethics Committee.  In 
addition, please ensure that any research assistants are knowledgeable about 
research ethics and confidentiality, and any co-investigators have completed human 
protection training within the past three years, and have forwarded their 
certificates to the IRB office (G. Duke).  
Please review the UT Tyler IRB Principal Investigator Responsibilities, and 
acknowledge your understanding of these responsibilities and the following 
through return of this email to the IRB Chair within one week after receipt of 
this approval letter:  
 
 This approval is for one year, as of the date of the approval letter 
 Request for Continuing Review must be completed for projects extending 
past one year 
 Prompt reporting to the UT Tyler IRB of any proposed changes to this 
research activity 
 Prompt reporting to the UT Tyler IRB and academic department 
administration will be done of any unanticipated problems involving 
risks to subjects or others 
 Suspension or termination of approval may be done if there is evidence of 
any serious or continuing noncompliance with Federal Regulations or any 
aberrations in original proposal. 
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 Any change in proposal procedures must be promptly reported to the IRB 
prior to implementing any changes except when necessary to eliminate 
apparent immediate hazards to the subject.  
 
Best of luck in your research, and do not hesitate to contact me if you need any 
further assistance. 
 
Sincerely, 
 
 
Gloria Duke, PhD, RN 
Chair, UT Tyler IRB 
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30 October 2013 
 
 
 
Dear 
 
Re: 26162: Cost-benefit Analysis of Tunneled Central Venous 
Catheter Dressings in Canadian Stem Cell Transplant Recipients 
 
Thank you for submitting the proposal for the above named study. On behalf of the 
I have reviewed the following 
documents as of 18 
October 2013: 
 
 Application for Research of Minimal Risk dated 11 October (received 16 
October 2013) 
 The University of Texas at Tyler Institutional Review Board 
Approval Letter and Application dated 10 October 2013 
 
Thank you also for your submission dated 25 October 2013 in response 
to correspondence dated 21 October 2013, together with the following: 
 
 Application for Research of Minimal Risk dated 25 October (received 25 
October 2013) As of 28 October 2013, the following documents have been 
approved: 
 Application for Research of Minimal Risk dated 25 October (received 25 
October 2013) 
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Please note that this approval is based on the following conditions: 
if there are any other changes to the protocol during the year, a letter  
describing the changes must be forwarded to the 
 an Annual Renewal form must be submitted two months prior to the 
deadline date of 18 October 2014 (one year from the date of initial  
 review) containing the information as per our annual renewal form; 
 a Final Report must be submitted at the termination of the project. 
 
 
The deliberations of the include all elements described in Section 50 of 
the Health Information Act, and this study was found to be in compliance with all 
the applicable requirements of the Act. Access to personal identifiable health 
information was requested in this ethics application, however upon review, the
 has waived consent as it was demonstrated to 
be impractical, unreasonable or not feasible to obtain. 
 
The complies with the following 
guidelines and regulations: 
 
 
 
 
 
 
 
 
 Tri-Council Policy Statement:  Ethical Conduct for Research Involving 
Humans; 
 Health Information Act which has been proclaimed on April 25, 2001 in 
 Health Canada, as defined in C.05 (Part C Division 5) (1024 - Clinical 
Trials) of the Food And Drug Regulations -Amendment and the 
Therapeutic Products Directorate Guidelines /ICH Harmonized Tripartite 
Guidelines - Good Clinical Practice: Consolidate Guidelines; 
 National Institutes of Health - Code of Federal Regulations (USA); and 
 Our institution has been approved by the Office for Human Research 
Protections in the United States. 
 
Members of the who are named as investigators or co/sub-investigators in 
research studies do not participate in discussion related to, nor vote on, such 
studies when they are presented to the . 
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Please accept the Committee’s best wishes for success in your 
research. Sincerely, 
 
 
 
 
 
Associate Chair, 
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The University of Texas at Tyler 
Institutional Review Board 
 
 
October 10, 2013 
 
 
Dear Ms Keeler, 
 
 
Your request to conduct the study:  Cost-benefit Analysis of Tunneled Central Venous 
Catheter Dressings in Canadian Stem Cell Transplant Recipients IRB #F2013-17 has 
been approved by The University of Texas at Tyler Institutional Review Board under 
expedited review. This approval includes a waiver of written informed consent, and is 
conditional on approval by the Alberta Cancer Research Ethics Committee.  In addition, 
please ensure that any research assistants are knowledgeable about research ethics and 
confidentiality, and any co-investigators have completed human protection training 
within the past three years, and have forwarded their certificates to the IRB office (G. 
Duke). 
 
Please review the UT Tyler IRB Principal Investigator Responsibilities, and 
acknowledge your understanding of these responsibilities and the following through 
return of this email to the IRB Chair within one week after receipt of this approval 
letter:  
 
 This approval is for one year, as of the date of the approval letter 
 Request for Continuing Review must be completed for projects extending past 
one year 
 Prompt reporting to the UT Tyler IRB of any proposed changes to this research 
activity 
 Prompt reporting to the UT Tyler IRB and academic department 
administration will be done of any unanticipated problems involving risks to 
subjects or others 
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 Suspension or termination of approval may be done if there is evidence of any 
serious or continuing noncompliance with Federal Regulations or any aberrations 
in original proposal. 
 Any change in proposal procedures must be promptly reported to the IRB prior to 
implementing any changes except when necessary to eliminate apparent 
immediate hazards to the subject. 
 
 
Best of luck in your research, and do not hesitate to contact me if you need any further 
assistance. 
 
Sincerely, 
 
 
 
Gloria Duke, PhD, RN 
Chair, UT Tyler IR
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Guidelines for Authors 
 
Introduction 
The Canadian Oncology Nursing Journal (CONJ) welcomes original articles, 
research papers, letters to the editor, media reviews, professional ads, and stories of 
interest to nurses who provide care to patients with cancer and their families. 
 
Policy 
All correspondence and manuscripts must be forwarded to the editor-in-chief. The 
editor-in-chief or delegated associate editors will assume responsibility for obtaining 
confidential peer review. Normally, the process of peer review takes approximately 
three months. If published, manuscripts become the property of CONJ. The journal 
will have exclusive rights to the manuscript and to its reproduction. Manuscripts 
may not be under consideration by any other journal. 
 
Copyright 
When submitting a manuscript, include a statement of ownership and assignment of 
copyright as follows: "I hereby declare that I am the sole proprietor of all rights to 
my original article entitled…, and I assign all rights to CANO/ACIO for publication 
in the Canadian Oncology Nursing Journal." Please date and sign. ALL authors must 
sign this statement. Please submit this statement in a WORD document by electronic 
mail to the editor in chief, CONJ. 
 
Authors must obtain written permission for use of previously published materials 
included in the manuscript. This includes extensive quotations (greater than 500 
words), tables, figures, charts, graphs, etc. Written permission for all copyright 
materials must be included with the manuscript. 
 
Manuscript Content 
1. Style 
Manuscripts must be typewritten or word processed in times roman or courier 
typeface using a 12 points font. Copy must be clear and legible. Uniform margins of  
  
89 
 
Appendix C (Continued) 
 
at least 1 inch, and double spacing are required. Number pages consecutively in 
upper right-hand corner, beginning with title page. Identify each page with the first 
two or three words from the title inserted above the pagination. Use one side of the  
paper only. The required style is that recommended by the American Psychological 
Association (APA). (2001). Publication manual (5th ed.). Washington, DC: Author. 
 
2. Length 
The preferred length is 6 to 16 double-spaced pages including tables, figures, and 
references. 
 
3. Title page 
The title page must include the title of the article, the name(s) of the author(s) as 
meant to appear in the publication, and, if possible, an e-mail address where the main 
or contact author may be reached. If more than one author, the order must be that 
desired in the publication. Accuracy is essential to ensure accuracy in publication. 
Include the author(s) credentials, position, place of employment, correct mailing 
address, telephone and facsimile numbers. Indicate preferred author and address for 
correspondence. 
 
1. Abstract 
Include an abstract of 100-120 words. This abstract should summarize the article and 
highlight the main points of interest for the reader. It must be double-spaced and on a 
separate page. 
 
2. References 
References must be double-spaced, in alphabetical order, complete, and accurate. 
References should start on a separate page and must be cited in the text. 
 
3. Tables 
Tables are numbered consecutively in the order in which they are first mentioned in the 
text. Double-space and begin each table on a separate page. Tables should complement, 
not duplicate text. 
 
4. Figures 
All figures must be copyrighted and documented. They must be submitted on separate 
pages and should not duplicate text.  Number consecutively in the order in which they are 
first mentioned in the text.  Figures must be clear, easy to interpret, and in black and 
white only for reproduction. 
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5. On acceptance for publication  
 
Manuscripts accepted for publication are subject to copyediting. Electronic copies should 
be on the Windows operating system and rich text format is preferred. 
 
Correspondence 
A letter of query to the editor-in-chief regarding suitability of a proposed manuscript is 
suggested, but not required. Forward the original complete manuscript in a WORD 
document by electronic mail to the editor-in-chief. Include your e-mail address and other 
contact addresses with your manuscript for acknowledgement of receipt of your 
manuscript. 
 
Non-refereed material 
The journal also invites brief submissions of less than 500 words that highlight clinical 
practice tips, new program developments, research in progress, or reviews of articles, 
books, and videotapes. These submissions are published at the discretion of the editor-in-
chief. Queries are unnecessary. 
 
Language 
Articles will be published in the language of submission with a summary in the other 
official language (French or English). Selected articles will be translated in total. The 
Canadian Oncology Nursing Journal is officially a bilingual publication. 
 
Heather Porter, RN, Ph.D.  hbporter@rogers.com Editor-in-Chief 
Canadian Oncology Nursing Journal (CONJ) 14-54 Blue Springs Drive 
Waterloo, ON N2J 4M4 Tel: (519) 886-8590 
Fax: (519) 886-9329
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Permission Letter 
2/17/2014 
 
Melanie Keeler 
1047 Maggie Street, SE Calgary, AB 
T2G4L8 Canadian Oncology Nursing 
Journal 
375 West 5th Avenue, Suite 201, Vancouver BC, V5Y 1J6 
 
Dear Dr. M. Fitch: 
 
I am preparing my dissertation at The University of Texas at Tyler, with plans to 
co1nplete my degree on May 9, 2014. We use a multi-paper format for our 
dissertation portfolio, which includes papers we have written and/or published. 
 
The article Central Line Practice in Canadian Blood and Marrow Cell Transplant, 
of which I am first author, is scheduled to appear in your Canadian Oncology 
Nursing Journal, reports an essential part of my dissertation research. I would like 
permission to reprint the article as a chapter in my dissertation portfolio. As per 
your preference, I can either include a pdf of the published article or a word 
document of the submitted article with reference to the journal. 
 
Following the final dissertation defense, our dissertation portfolios are submitted 
to our institutional repository and access may be restricted to those currently 
employed or enrolled at The University of Texas at Tyler.  The copyright for the 
article named above remains with the Canadian Oncology Nursing Journal. 
Submission to our institutional repository will in no way restrict republication of 
the material in any other form by you or by others authorized by you
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If you have any questions, please contact me at mkeeler@patriots.uttyler.edu  or  
my dissertation chair, Dr. B. Haas at bhaas@uttyler.edu. Thank you for your 
assistance, 
 
 
Melanie Keeler 
RN, PhD candidate a t the University of Texas  
I hereby give permission for the use as requested above: 
x 
Marg Fitch  
Editor In Chief CONJ 
x 
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DEGREE 
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A. Personal Statement 
The goal of the proposed research was to investigate Canadian blood and marrow cell 
transplant nursing practice with central venous catheters in terms of cost.  Specifically, 
we measured differences in catheter-related bloodstream infection across six-year period 
in a cohort of adult blood and marrow transplant recipients with long-term tunneled triple 
lumen subclavian central venous catheters that used different types of dressings 
(transparent, no dressing, or gauze).  Concomitant analysis of the cost of infection and 
cost of each dressing strategy was conducted. My clinical background in hem-oncology 
nursing and post-graduate coursework in nursing and research enabled me to successfully 
carry out the study.   
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